Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey

被引:48
|
作者
Potpara, Tatjana S. [1 ,2 ]
Dan, Gheorghe-Andrei [3 ]
Trendafilova, Elina [4 ]
Goda, Artan [5 ]
Kusljugic, Zumreta [6 ]
Manola, Sime [7 ]
Music, Ljilja [8 ]
Musetescu, Rodica [9 ]
Badila, Elisabeta [10 ]
Mitic, Gorana [11 ]
Paparisto, Vilma [5 ]
Dimitrova, Elena S. [4 ]
Polovina, Marija M. [1 ,2 ]
Petranov, Stanislav L. [12 ]
Djergo, Hortensia [5 ]
Loncar, Daniela [6 ]
Bijedic, Amira [6 ]
Brusich, Sandro [13 ]
Lip, Gregory Y. H. [1 ,2 ,14 ]
机构
[1] Univ Belgrade, Sch Med, Belgrade, Serbia
[2] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
[3] Med Univ Carol Davila, Colentina Univ Hosp, Bucharest, Romania
[4] Natl Heart Hosp, Sofia, Bulgaria
[5] Univ Hosp Ctr Mother Theresa, Clin Cardiol, Tirana, Albania
[6] Clin Internal Dis, Dept Cardiol, Tuzla, Bosnia & Herceg
[7] Clin Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia
[8] Univ Clin Ctr Podgorica, Podgorica, Montenegro
[9] Cty Emergency Hosp, Ctr Cardiol, Craiova, Romania
[10] Med Univ Carol Davila, Dept Internal Med, Emergency Clin Hosp, Bucharest, Romania
[11] Clin Ctr Vojvodina, Novi Sad, Serbia
[12] Multiprofile Hosp Act Treatment, Burgas, Bulgaria
[13] Clin Hosp Ctr Rijeka, Rijeka, Croatia
[14] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
EUROPEAN COUNTRIES; FOLLOW-UP; MANAGEMENT; ANTICOAGULATION; RISK; ASPIRIN; PROGNOSIS; MORTALITY; WARFARIN; REGISTRY;
D O I
10.1038/srep20432
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Data on the management of atrial fibrillation (AF) in the Balkan Region are limited. The Serbian AF Association (SAFA) prospectively investigated contemporary 'real-world' AF management in clinical practice in Albania, Bosnia&Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia through a 14-week (December 2014-February 2015) prospective, multicentre survey of consecutive AF patients. We report the results pertinent to stroke prevention strategies. Of 2712 enrolled patients, 2663 (98.2%) with complete data were included in this analysis (mean age 69.1 +/- 10.9 years, female 44.6%). Overall, 1960 patients (73.6%) received oral anticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs. Of patients given OAC, 17.2% received non-vitamin K antagonist oral anticoagulants (NOACs). CHA(2)DS(2)-VASc score was not significantly associated with OAC use. Of the 'truly low-risk' patients (CHA(2)DS(2)-VASc = 0 [males], or 1 [females]) 56.5% received OAC. Time in Therapeutic Range (TTR) was available in only 18.7% of patients (mean TTR: 49.5% +/- 22.3%). Age = 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use. Our survey shows a relatively high overall use of OAC in AF patients, but with low quality of vitamin K antagonist therapy and insufficient adherence to AF guidelines. Additional efforts are needed to improve AF-related thromboprophylaxis in clinical practice in the Balkan Region.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Real - world evidence of stroke prevention in patients with non-valvular atrial fibrillation
    Coleman, C.
    Antz, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 502 - 502
  • [32] Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines
    Armaganijan, Luciana
    Patel, Dimpi
    Dietrich, Cristiano
    Morillo, Carlos A.
    PHARMACEUTICALS, 2012, 5 (04) : 384 - 397
  • [33] Stroke prevention in atrial fibrillation: comparison of recent international guidelines
    Chao, Tze-Fan
    Nedeljkovic, Milan A.
    Lip, Gregory Y. H.
    Potpara, Tatjana S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0O) : 53 - 60
  • [34] Real-world adherence to oral anticoagulants in atrial fibrillation
    Simonyi Gabor
    Paksy Andras
    Varnai Reka
    Medvegy Mihaly
    ORVOSI HETILAP, 2020, 161 (20) : 839 - 845
  • [35] Management of stroke prevention in Bulgarian patients with non-valvular atrial fibrillation (BUL-AF Survey)
    Runev, Nikolay Margaritov
    Dimitrov, Stamen Mitev
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 187 : 683 - 685
  • [36] Guideline adherence for stroke prevention and risk of mortality in patients with atrial fibrillation
    Chao, T. F.
    Lip, G. Y. H.
    Chen, S. A.
    EUROPEAN HEART JOURNAL, 2015, 36 : 907 - 908
  • [37] Mortality and stroke prevention in atrial fibrillation; network meta-analysis of real world data
    Komocsi, A.
    Sharif, S.
    Kehl, D.
    Molnar, Z.
    Vorobcsuk, A.
    EUROPEAN HEART JOURNAL, 2018, 39 : 695 - 695
  • [38] Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban
    Camm, A. John
    Coleman, Craig I.
    Larsen, Torben Bjerregaard
    Nielsen, Peter Bronnum
    Tamayo, Sally
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 : S45 - S60
  • [39] Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment
    Mert, Kadir U.
    Mert, Gurbet O.
    Basaran, Ozcan
    Beton, Osman
    Dogan, Volkan
    Tekinalp, Mehmet
    Aykan, Ahmet C.
    Kalaycioglu, Ezgi
    Bolat, Ismail
    Tasar, Onur
    Safak, Ozgen
    Kalcik, Macit
    Yaman, Mehmet
    Kirma, Cevat
    Biteker, Murat
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 (06) : 428 - 438
  • [40] Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
    Paikin, Jeremy S.
    Manolakos, Joshua J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 965 - 972